When: Close below $385 OR time-stop fires OR weekly close below $350

Then: Downgrade to Underweight with 50-55% trim + $380 puts hedge on residual

When: Weekly close below $349.61

Then: Move promptly to Underweight

HOLD. Don't initiate new longs. Trim into any relief rally toward four hundred to four ten. Wait for the stock to reclaim the fifty SMA with conviction, wait for MACD to confirm a bullish cross, wait for at least one catalyst to resolve in a way that confirms rather than threatens the recovery thesis.

• Price target implied twenty six to thirty two percent upside vs ten percent downside to three fifty, but the real risk is path risk: stock failing at the fifty SMA three times, rejected at four ten, sitting on lower Bollinger band with MACD still negative
• Technical setup is NOT a Bollinger band launchpad: price testing lower band for first time after breaking below fifty SMA, RSI bounced from thirty three to fifty but now at forty point eight four (dead cat bounce), MACD histogram at zero point three nine is statistical noise
• Valuation at seventeen point three times forward multiple is vulnerable to expansion to twenty or twenty one times if forward EPS estimates of twenty two forty four miss again (estimates have missed two years running)
• Overhead resistances at four zero five, four ten, and four twenty five provide sellers multiple opportunities to lean in before any upside materializes
• TPG deal timing (selling stake in segment that derailed profits hours before guidance reaffirmation) damages management credibility; AI spend is at Optum Insight, different unit from WellMed clinics being sold
• Buybacks declined to one point six five billion for the quarter vs nine billion in twenty twenty four, reducing stock price support at exactly the wrong technical moment
• Stop loss at three eighty five vs current price three eighty eight provides essentially zero margin of safety
• Event calendar unfavorable: fifty percent odds of three point four percent CPI print tomorrow (coin flip binary event), Q3 earnings in five weeks with elevated medical costs and sector headwinds, prior auth changes October first largely already priced in

→ vs aggressive: Asymmetric risk-reward framing is wrong; the twenty six to thirty two percent upside vs ten percent downside ignores path risk of algorithmic selling cascades if support breaks, not a clean two hundred SMA test

→ vs aggressive: Bollinger band launchpad thesis is confidently wrong; this is a test of support that hasn't held yet, not a confirmed higher low; lower highs and lower lows forming since mid July confirm bearish pattern

→ vs aggressive: UNH quality premium vs Cigna doesn't protect against forward EPS estimate misses; when estimates miss again, seventeen point three times multiple expands to twenty or twenty one times and stock drops ten percent on multiple alone

→ vs aggressive: TPG deal is not a capital partnership proof; selling WellMed clinics while spending one point five billion on AI at Optum Insight are independent decisions (different business units), not evidence of operational commitment

→ vs aggressive: Declining buybacks signal less capacity to support stock, not discipline; management choosing to underinvest in own equity at three eighty five when annual buybacks were nine billion in twenty twenty four is a bearish capital allocation signal

→ vs aggressive: Event calendar catalysts do not favor bulls; CPI is a coin flip with downside skew, Q3 earnings setup unfavorable with estimates missing two years running, and prior auth changes largely priced in with modest impact

Maintain benchmark weight; do not add new longs at $388 with stop at $385 due to structurally poor risk-reward; do not trim aggressively; set explicit triggers at $385 breakdown and $405 reclaim; hold through 9/11 CPI print; let market data resolve ambiguity rather than forcing a view today.

• H1 2026 print up 104% year-over-year is real
• 200 SMA at $350 provides structural floor
• FCF engine at $24.3 billion is powerful and deleveraging trajectory is genuine
• Forward EPS estimate of $22.44 is a hypothesis that needs to survive next two earnings prints, not a fact
• UNH trades at more than 2x Cigna's earnings multiple while having slowest revenue growth creates real arbitrage risk
• UNH is a $348 billion mega-cap with beta of 0.62 and $24.3 billion in annual FCF—these stocks don't gap down through major moving averages on no volume
• Current entry at $388 with stop at $385 gives essentially no room to be wrong
• Explicit trigger: close below $385 on volume = trim to underweight; next support is 200 SMA at $350 with no nearby floors
• Explicit trigger: close above $405 with 10 EMA reclaim = add modestly toward benchmark-plus because technical setup shifts bullish with confirmation
• Hold through 9/11 CPI print regardless of action—market reaction to print is more important than print itself
• TPG deal is ambiguous—watch how management frames it on next earnings call; characterize as 'exploring strategic partnerships' = warning sign; characterize as one-off fix = neutral to positive
• On buybacks: if they resume at $4-5 billion per quarter after deleveraging hits target = major positive signal; if stay at $1-2 billion = conservative interpretation validated
• Right approach is to size into catalysts (add after clean CPI, before Q3 earnings) rather than around them
• Today's price is not the right place to be making big moves

→ vs aggressive: Forward EPS estimate of $22.44 is treated as fact when it's actually a hypothesis that needs to survive two earnings prints—if cut to $20 during Q3, the $515 target becomes $440-$460

→ vs aggressive: Dismissal of valuation concerns is too clean—quality at wrong price is still a bad trade; UNH at more than 2x Cigna's earnings multiple with slowest growth creates compression risk on $348 billion market cap

→ vs aggressive: TPG deal interpretation is the most charitable possible framing—bear case is selling a stake in unit that broke numbers right before reaffirming guidance; market read it as 3% selloff

→ vs conservative: RSI at 40.84 bouncing from 33 to 50 over five trading days shows buyers stepping in, not a dead cat—characterizing it as 'dead cat bounce within bearish momentum regime' is editorializing the data

→ vs conservative: MACD histogram flip at 0.39 dismissed as 'statistical noise' when it's the first positive histogram reading in weeks—embracing three bearish technical reads while dismissing one bullish as noise is selection bias

→ vs conservative: UNH is a $348 billion mega-cap with beta of 0.62 and $24.3 billion in annual FCF—these stocks don't gap down through major moving averages on no volume; 'algorithms start running' framing imports behavioral patterns from wrong asset class

→ vs conservative: Valuation compression argument overstates risk—assumes entire multiple expansion hits at once which only happens on true earnings shock, not modest cost elevation

→ vs conservative: Pricing in worst-case scenario as base case—management said MA is strong, Medicaid tracking favorably, Optum Health improving; not a setup for 10% air pocket